Doctor's are able to micromanage their patients' dosage of bioidentical hormones using compounding pharmacies such as Advantge Pharmaceuticals in Rocklin.

Fountain of Youth

The role of bioidentical hormones during menopause

Unless you get on the wrong airplane or harbor a relentless cancer, doctors say you can pretty much count on living to be 90. A hundred years ago, it was age 50. For many women, that would have meant dying before menopause. Now it means living half a lifetime with hormones on the fritz.

Sep 30, 2010 Christine Calvin
Dr. Jan Nolta heads he stem cell program for the UC Davis Health System and directs the Institute for Regenerative Cures. 

(Photo courtesy of UC Davis Health System)

Stemming Out

UC Davis researchers deliver lab innovations

Dr. Jan Nolta is a whirlwind of energy, and this July morning she is blitzing through UC Davis’ brand-new Institute for Regenerative Cures, a state-of-the-art lab where scientists and researchers are working on breakthrough discoveries and stem cell therapies.

Jul 31, 2010 Josh Brodesky
Jason Moulton, CEO, Home Team Financial Inc.

Get Onto My Cloud

Moving to virtual space for software, storage and more

As a chief executive of a real estate and brokerage firm, Jason Moulton faced some hard financial decisions in 2009.

Among the cost-saving measures Moulton implemented was to move all operations to the clouds, or virtual, rather than physical hardware and software.

As a chief executive of a real estate and brokerage firm, Jason Moulton faced some hard financial decisions in 2009.

Among the cost-saving measures Moulton implemented was to move all operations to the clouds, or virtual, rather than physical hardware and software.

Jun 30, 2010 Andrea Lorenz
Vikram Janardhan, CEO, Insera Therapeutics; and Cary Adams, founder of, Proximal Ventures.

Stayin’ a Life

Will the health care overhaul affect investment in medical technology?

After four quarters of increasing venture investment, 2010 is off to a slow start. Venture capitalists invested $4.7 billion in the year’s first quarter, down from $5.2 billion in the fourth quarter of 2009, according to PricewaterhouseCoopers. The life sciences sector, including biotechnology and medical device industries, took the biggest hit with a 26 percent decline in venture investment over the previous quarter.

May 31, 2010 Christine Calvin